Pharmacology British Journal of Pharmacology

Redox and immune gene variants help explain who develops NSAID hypersensitivity, and which type

  • A Spanish case-control study compared people with confirmed NSAID hypersensitivity against tolerant controls, testing variants in antioxidant and immune genes with a replication cohort.
  • Cross-reactive reactions pointed to glutathione-handling genes, with a GSTM5 genotype tracking lower serum enzyme activity.
  • Reactions to a single NSAID instead implicated SOD1, AKR1C3 and IL4R, suggesting distinct biology for each phenotype.
Points Based on the abstract

Serum GST activity tracking GSTM5 genotype is a nice functional hook, but serum is not the immune or skin tissue where the reaction happens, and no drug-challenge or ex vivo cell data link the enzyme to the phenotype. Before calling this causal, I'd want replication in a non-Spanish cohort and a test of whether SOD1 or IL4R variants shift T-cell or basophil responses to the culprit NSAID.